[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.] #  @chuminhua432 Minhua Chu Minhua Chu posts on X about china, the first, qiming venture partners, $onc the most. They currently have XXXXX followers and XX posts still getting attention that total XXXXX engagements in the last XX hours. ### Engagements: XXXXX [#](/creator/twitter::3643934180/interactions)  - X Week XXXXXX -XX% - X Month XXXXXX -XX% - X Months XXXXXXX +39% - X Year XXXXXXX +397% ### Mentions: XX [#](/creator/twitter::3643934180/posts_active)  - X Week XX -XX% - X Month XXX -XX% - X Months XXX +20% - X Year XXX +79% ### Followers: XXXXX [#](/creator/twitter::3643934180/followers)  - X Week XXXXX +0.77% - X Month XXXXX +2.80% - X Months XXXXX +40% - X Year XXXXX +130% ### CreatorRank: XXXXXXX [#](/creator/twitter::3643934180/influencer_rank)  ### Social Influence **Social category influence** [stocks](/list/stocks) XXXXX% [countries](/list/countries) XXXXX% [finance](/list/finance) XXXXX% [vc firms](/list/vc-firms) #72 [travel destinations](/list/travel-destinations) XXXX% [currencies](/list/currencies) XXXX% [cryptocurrencies](/list/cryptocurrencies) XXXX% [technology brands](/list/technology-brands) XXXX% **Social topic influence** [china](/topic/china) 11.11%, [the first](/topic/the-first) 5.56%, [qiming venture partners](/topic/qiming-venture-partners) #1, [$onc](/topic/$onc) #9, [shanghai](/topic/shanghai) #146, [$azn](/topic/$azn) 3.7%, [$smmt](/topic/$smmt) #11, [os](/topic/os) 3.7%, [at least](/topic/at-least) 1.85%, [pts](/topic/pts) XXXX% **Top accounts mentioned or mentioned by** [@pistoto2017](/creator/undefined) [@parklover_ja](/creator/undefined) [@jacobplieth](/creator/undefined) [@oncodailyio](/creator/undefined) **Top assets mentioned** [One Cash (ONC)](/topic/$onc) [AstraZeneca PLC (AZN)](/topic/$azn) [Summit Therapeutics Inc. Common Stock (SMMT)](/topic/$smmt) [Johnson & Johnson (JNJ)](/topic/$jnj) [Neurocrine Biosciences, Inc. (NBIX)](/topic/$nbix) [Eli Lilly and Company (LLY)](/topic/$lly) [AbbVie Inc (ABBV)](/topic/$abbv) [Pfizer, Inc. (PFE)](/topic/$pfe) ### Top Social Posts Top posts by engagements in the last XX hours "@JacobPlieth It's from Gracell Biotech. $AZN acquired Gracell in Dec. 2023" [X Link](https://x.com/chuminhua432/status/1994433875075100776) 2025-11-28T15:51Z 3019 followers, XXX engagements "#3SBio published the Ph2 results of SSGJ-707 #SSGJ707 a bispecific antibody targeting PD-1 and VEGF as a monotherapy in patients with advanced NSCLC . Among the XX pts completed at least one efficacy evaluation ORR and DCR were XXXX% (8/27)/85.2% (23/27) 61.8%(21/34)97.1% (33/34) XXXX% (6/11)/90.9% (10/11) and XX% (1/4)/75% (3/4) at doses of 5mg/kg Q3W 10mg/kg Q3W 20mg/kg Q3W and XX mg/kg Q3W respectively. Select subgroups are summarized in SSGJ-707 10mg/kg Q3W. The ORR were XXXX% (12/22) and 75%(9/12) in non-squamous and squamous pts respectively" [X Link](https://x.com/chuminhua432/status/1925826076023882183) 2025-05-23T08:08Z 3025 followers, 12K engagements "#Akeso said in its H1 2025 report its lung cancer drug ivonescimab (PD-1/EGFR) for the first time clearly extended overall survival (OS) in a pivotal study. The final analysis of the Phase III HARMONi-A trial met its OS goal showing that ivonescimab delivered "a statistically significant and clinically meaningful OS benefit."" [X Link](https://x.com/chuminhua432/status/1960530603306311912) 2025-08-27T02:31Z 3024 followers, 9776 engagements "$JNJ reported 2025 Q3 earnings XXX% sales increase to $XX billion BCMA CAR-T therapy Carvyktideveloped in partnership with Legend Biotechsaw significant sales growth. Carvykti achieved total sales of $XXX million in Q3 2025 marking an XXXX% yoy increase. Carvykti's sales have already surpassed $X billion this year totaling $XXXXX billion exceeded its full-year total from 2024 which was $XXX million" [X Link](https://x.com/chuminhua432/status/1978396388808593549) 2025-10-15T09:43Z 3022 followers, 3021 engagements "Nanjing-based TransThera Sciences announced to enter into a royalty bearing patent assignment and research collaboration agreement with Neurocrine Biosciences $NBIX to develop NLRP3 inhibitors one of the Companys preclinical assets for multiple diseases. ex-Greater China develop manufacture and commercialize rights total potential value of up to US$881.5 million" [X Link](https://x.com/chuminhua432/status/1985607410455875590) 2025-11-04T07:17Z 3024 followers, 1205 engagements "Ivacta bio an in vivo cell therapy developer announced the completion of an angel round financing exceeding XXX million RMB led by Qiming Venture Partners. Ivacta was was spun off from the in vivo CAR-T platform of GRIT Bio on June XX 2025. Ivacta's in vivo CAR-T therapy developed based on a targeted LNP delivery system focuses on delivering revolutionary treatment options for hematological malignancies and autoimmune diseases" [X Link](https://x.com/chuminhua432/status/1986048072338829580) 2025-11-05T12:28Z 3024 followers, XXX engagements "3SBio updated Ph2 clinical data for its PD-1/VEGF BsAb SSGJ-707 + chemo in 1L NSCLC at #SITC2025 LBA abstract. SSGJ-707 XX mg/kg the confirmed objective response rate (ORR) was XXXX% in nonsquamous XXXX% in squamous cohort A and XXXX% (paclitaxel; majority pending confirmation) and XXXX% (nab-paclitaxel) in squamous cohort B; with tislelizumab confirmed ORR was XXXX% in nonsquamous and XXXX% in squamous patients. Responses were observed irrespective of PD-L1 expression" [X Link](https://x.com/chuminhua432/status/1986813318112350433) 2025-11-07T15:09Z 3025 followers, XXX engagements "#SITC2025 LBA Final overall survival analysis of HARMONi-A study comparing ivonescimab plus chemotherapy to chemotherapy alone in patients with EGFR+ NSCLC progressed on EGFR-TKI treatment Akeso $SMMT median OS was XXXX months (95% CI: XXXX 20.0) in the ivonescimab + chemotherapy group vs XXXX months (95% CI: XXXX 16.3) in the placebo + chemotherapy group with a hazard ratio of XXXX (95% CI : XXXX 0.95) and P=0.019 (two-sided) achieving statistical significance at the pre-specified alpha level of XXXX. The 12-month 24-month and 30-month OS rates were XXXX% vs XXXX% XXXX% vs XXXX% and XXXX% vs" [X Link](https://x.com/chuminhua432/status/1986832222910136358) 2025-11-07T16:24Z 3024 followers, 1030 engagements "$SMMT and Akeso published results from the Ph3 HARMONi-A trial conducted in China and sponsored by Akeso featuring PD-1xVEGF bispecific antibody ivonescimab. The data was presented #SITC2025. The First Phase III Study Testing Ivonescimab Now Represents the First Statistically Significant OS Benefit Achieved by an Ivonescimab Containing Regimen Ivonescimab Plus Chemotherapy Demonstrates Median OS of XXXX Months vs. XXXX Months Respectively for Patients Receiving Ivonescimab Plus Chemotherapy vs. Chemotherapy Alone; OS HR of XXXX (p=0.019)" [X Link](https://x.com/chuminhua432/status/1987542110191735143) 2025-11-09T15:25Z 3024 followers, 4164 engagements "Akeso's Bispecific Antibody Targeting A and BBB-Expressed Receptor Approved for Alzheimer's Disease Clinical Trials in China It is Akeso's first innovative therapeutic candidate designed to target CNS" [X Link](https://x.com/chuminhua432/status/1990328310203847030) 2025-11-17T07:57Z 3025 followers, 8259 engagements "Innovent Biologics announced that mazdutide (IBI362) a dual GLP-1/glucagon receptor agonist met the primary endpoint and all key secondary endpoints in the Phase X GLORY-2 study in Chinese adults with moderate-to-severe obesity (BMI XX kg/m or XX kg/m with weight-related comorbidities). At Week XX the mazdutide X mg group achieved a mean weight reduction of XXXXX% compared to XXXX% in the placebo group. XXXX% of participants in the mazdutide X mg group achieved a weight reduction of XX% or more versus XXX% in the placebo group (P0.0001 for all comparisons). The key secondary endpoints" [X Link](https://x.com/chuminhua432/status/1991412215493406964) 2025-11-20T07:44Z 3024 followers, 5442 engagements "$ONC announced that FDA has accepted and granted Priority Review to a NDA for sonrotoclax a next-generation BCL2 inhibitor for the treatment of adult patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL) following treatment with a Brutons tyrosine kinase (BTK) inhibitor" [X Link](https://x.com/chuminhua432/status/1994067887976558844) 2025-11-27T15:36Z 3024 followers, 1519 engagements "Using ADCs to deliver RAS inhibitors has emerged as a hotspot in drug development due to its ability to broaden the therapeutic window and minimize off-target toxicity. According to patent information (WO2025/051241 A1) GenFleet Therapeutics is developing an EGFR/HER3 bispecific antibody-ADC carrying a pan-RAS inhibitor payload. Now at the recent AACR-NCI-EORTC 2025 conference Adlai Nortye $ANL unveiled its Pan-RAS(ON)-conjugated ADC candidate AN4035. /1 🧵👇🏻" [X Link](https://x.com/chuminhua432/status/1995158975629898036) 2025-11-30T15:52Z 3024 followers, 6940 engagements "5/ Bystander Effect Cytotoxic against XX cancer cell lines regardless of KRAS mutation status Stronger bystander killing compared to topoisomerase inhibitor payloads" [X Link](https://x.com/chuminhua432/status/1995158998031753216) 2025-11-30T15:52Z 3024 followers, XXX engagements "6/ Efficacy HPAC and CL40 CDX models: X mg/kg single dose XX% tumor regression XX mg/kg 8589% regression Across XX NSCLC CRC and pancreatic cancer PDX models: Overall antitumor response rate of 73%" [X Link](https://x.com/chuminhua432/status/1995159003865985348) 2025-11-30T15:52Z 3024 followers, XXX engagements "Keymed Biosciences previously disclosed two ADCs: - CMG901 (AZD-0901 sonesitatug vedotin) a CLDN18.2-targeted ADC co-developed with Lepu Biopharma which entered a global collaboration with $AZN in 2023. - CM518D1 a CDH17-targeted ADC for which an IND was filed in China in January 2025. Recently published PCT patent WO2025/242098 reveals Keymeds third ADC candidate a CEACAM5-targeted ADC. - The humanized lead mAb1 H6K3 exhibits stronger binding affinity to both human and cynomolgus monkey CEACAM5 than the reference antibody (ref1). - No cross-reactivity with mouse CEACAM5 or other CEACAM" [X Link](https://x.com/chuminhua432/status/1995164405139694047) 2025-11-30T16:13Z 3021 followers, 2803 engagements "Hengrui announced that it nominated and appointed Guoxin Zhu former Vice President of Molecule Discovery Lilly Research Laboratories $LLY as its senior vice president" [X Link](https://x.com/chuminhua432/status/1996605998082277406) 2025-12-04T15:42Z 3025 followers, 1009 engagements "NHSA unveiled an updated version of its national medical insurance drug list and the inaugural edition of the commercial insurance innovative drug list. New lists will be formally implemented nationwide starting January X 2026. The updated national medical insurance drug list has added XXX drugs among which XX are innovative pharmaceuticals. The commercial insurance innovative drug list included XX drugs for the treatment of tumors rare diseases and Alzheimer's among others. The XX drugs are: X. Velaglucerase beta CANbridge X. Sapropterin Shandong New Time Pharma X. Teduglutide $TAK 4." [X Link](https://x.com/chuminhua432/status/1997686562528882919) 2025-12-07T15:16Z 3022 followers, 1578 engagements "SynRx Therapeutics announced the completion of a Series A #financing round exceeding RMB XXX million led by the Zhejiang 4+1 Biomedical and High-End Medical Device Industry Fund. SynRx Therapeutics has concentrated on unmet clinical needs in the DNA damage repair space. Its core product SYN818 is a highly selective DNA polymerase (Pol) inhibitor. It has entered Phase 1b clinical trials where it is being evaluated in combination with olaparib in patients with locally advanced or metastatic solid tumors with BRCA mutations and/or homologous recombination repair pathway defects. The companys" [X Link](https://x.com/chuminhua432/status/1998059544971559149) 2025-12-08T15:58Z 3023 followers, XXX engagements "yes Ascletis said when ASC30 was titrated weekly its vomiting rate was about half that of $LLY's oral GLP-1 orforglipron. The findings suggest "a potential best-in-class profile of ASC30 for both weight loss and GI tolerability" said Jinzi Jason Wu founder CEO and chairman of Ascletis" [X Link](https://x.com/chuminhua432/status/1998321106546032886) 2025-12-09T09:17Z 3024 followers, XX engagements "$ONC and $ABBV s Pharmacyclics have decided to voluntarily dismiss the patent lawsuit the Big Pharma firm brought against its competitor over their BTK inhibitors. BeOne announced the decision in a securities filing to HKSE. The move comes after the U.S. Patent and Trademark Office (USPTO) recently invalidated all claims of AbbVies patent No. 11672803 which underpinned the Illinois pharmas patent infringement lawsuit filed in 2023" [X Link](https://x.com/chuminhua432/status/1974136578315595864) 2025-10-03T15:36Z 3024 followers, 1001 engagements "$ZLAB Zai Lab has registered its first Ph3 clinical trial of ZL-1310 (zocilurtatug pelitecan) This randomized open-label clinical trial (n=665) aims to evaluate the efficacy and safety of ZL-1310 (at two dose levels) compared with investigator's choice (Tarlatamab Topotecan Lurbinectedin or Amrubicin) in patients with relapsed SCLC. The primary endpoints are cORR and OS. ZL-1310 is an ADC targeting DLL3 discovered by MediLink Therapeutics using its TAMLIN technology platform. In April 2023 Zai Lab and MediLink Therapeutics entered an agreement acquiring global rights for ZL-1310. In ASCO2025" [X Link](https://x.com/chuminhua432/status/1980616444850368962) 2025-10-21T12:45Z 3024 followers, 3688 engagements "Shanghai Longwood Biopharmaceuticals announced the completion of a Series B+ #financing worth hundreds of millions of RMB led by Qiming Venture Partners. Longwood was founded in 2012 by Dr. Wang Zhe. Dr. Zhe Wang a professor at Nankai University and an expert in medicinal chemistry. He completed his postdoctoral research at Harvard University under the tutelage of Nobel Laureate in Chemistry Elias J. Corey. Longwood focuses on the development of innovative drugs in the fields of immunotherapy antiviral therapy autoimmune diseases and tumor immunotherapy. Its core products: LW231 bi-functional" [X Link](https://x.com/chuminhua432/status/1983564447257170257) 2025-10-29T15:59Z 3024 followers, XXX engagements "ESMO Asia 2025: Hansoh Pharmaceutical will deliver an oral presentation featuring the first clinical data for its B7H3-targeted ADC HS-20093 (GSK5764227) in a NSCLC subgroup This ESMO Asia presentation reports results from the NSCLC cohort of ARTEMIS-001 treated with XXX or XXXX mg/kg HS-20093 every X weeks (Q3W). As of the data cutoff (January XX 2025) among XXX NSCLC patients treated at XXX mg/kg (n=93) or XXXX mg/kg (n=74): - XXXX% had adenocarcinoma XXXX% had squamous cell carcinoma - Median age: XXXX years - XXXX% current or former smokers - XXXX% with baseline brain metastases - Median" [X Link](https://x.com/chuminhua432/status/1996221634542444843) 2025-12-03T14:15Z 3024 followers, 2099 engagements "Kelun-Biotech and Crescent Biopharma Announce Strategic Partnership to Develop and Commercialize Novel Oncology Therapeutics Crescent has granted Kelun-Biotech exclusive rights to research develop manufacture and commercialize CR-001 (PD-1 x VEGF bispecific antibody) in Greater China. Kelun-Biotech has granted Crescent exclusive rights to research develop manufacture and commercialize SKB105 (ITGB6 ADC) in the United States Europe and all other markets outside of Greater China. The partnership includes the development of these candidates as monotherapies and also the evaluation of CR-001 in" [X Link](https://x.com/chuminhua432/status/1996608225551249698) 2025-12-04T15:51Z 3023 followers, XXX engagements "Cathay Capital has announced that it is leading Hundreds of millions of RMB Series A financing round for EMBIOS through its Sanofi-Cathay Healthcare Innovation Fund. EMBIOS has pioneered a key pipeline centered on the CXCR3 pathway. Its lead candidate YSC001 is designed around this pathway: on one hand it blocks the binding of CXCR3 to its ligands reducing the abnormal migration of immune cells to lesion sites; on the other it selectively eliminates these cells. EMBIOS submitted IND application for YSC001 last month. Sanofi Cathay Healthcare Innovation Fund:" [X Link](https://x.com/chuminhua432/status/1997887856321454405) 2025-12-08T04:35Z 3024 followers, 1647 engagements "BeOne Medicines (formerly BeiGene) $ONC registered an international Ph1 clinical trial for BG-75098 monotherapy or in combination for the treatment of advanced solid tumors. This Ph1 trial plans to enroll XXX patients with advanced solid tumors. The combination therapy regimens include combination with the CDK4 inhibitor BGB-43395 and fulvestrant. According to information disclosed by BeOne at its 2025 R&D Day BG-75098 is a CDK2 CDAC and also a potential first-in-class CDK2 degrader featuring superior potency selectivity and pharmacokinetic (PK) characteristics" [X Link](https://x.com/chuminhua432/status/1988271651327541736) 2025-11-11T15:44Z 3023 followers, 1390 engagements "SanegeneBio a clinical-stage biotech developing RNAi therapeutics announced the closing of Series B #financing round raising over $XXX million. The Series B financing was led by a well-known industrial investor. SanegeneBio has R&D operations in Boston Shanghai and Suzhou. The company has initiated clinical trials for four experimental medicines to-date and has LEAD tissue-selective RNAi delivery technology" [X Link](https://x.com/chuminhua432/status/1998061880338976995) 2025-12-08T16:07Z 3024 followers, 8198 engagements "$PFE announced it has entered into an exclusive global collaboration and license agreement with YaoPharma a subsidiary of Shanghai Fosun Pharmaceutical for the development manufacturing and commercialization of YP05002 a small molecule GLP-1 receptor agonist currently in Phase X development for chronic weight management. upfront: $XXX million milestones: up to $XXXXX billion Pfizer plans to conduct combination studies of YP05002 with its glucose-dependent insulinotropic polypeptide receptor (GIPR) antagonist PF-07976016 currently in Phase X development and with other small molecules in its" [X Link](https://x.com/chuminhua432/status/1998619207563722789) 2025-12-10T05:02Z 3024 followers, 2590 engagements "I also have a CRO (clinical study service) company and monitor some trials for GLP-1R drugs. Serious or frequently vomit and diarrhea commonly lead the patients cannot receive higher dosage it is a problem to those severe obesity patients. Of course in China BMI30 patients is relatively rare" [X Link](https://x.com/chuminhua432/status/1998620858458472734) 2025-12-10T05:08Z 3024 followers, XX engagements "D3 Bio a global clinical-stage biotech focused on the discovery and development of innovative oncology therapeutics announced the completion of a $XXX million Series B #financing round. The funding round was backed by IDG Capital and SongQing Capital. Existing investors WuXi AppTec's Corporate Venture Fund Temasek HSG MPCi and Medicxi also contributed to the round. Lead asset elisrasib (D3S-001) is KRAS G12C inhibitor" [X Link](https://x.com/chuminhua432/status/1998723191179825234) 2025-12-10T11:55Z 3024 followers, 1349 engagements "Elpiscience presented phase X clinical trial results for its internally developed bispecific antibody ES014 in an oral presentation at the ESMO Asia 2025. ES014 is a first-in-class CD39/TGF- bispecific antibody Among the X DT patients treated with ES014 X achieved partial response (PR) and X achieved stable disease (SD) resulting in an objective response rate (ORR) of XX% and a disease control rate (DCR) of 100%" [X Link](https://x.com/chuminhua432/status/1998740476883775709) 2025-12-10T13:03Z 3024 followers, XXX engagements
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
@chuminhua432 Minhua Chu
Minhua Chu posts on X about china, the first, qiming venture partners, $onc the most. They currently have XXXXX followers and XX posts still getting attention that total XXXXX engagements in the last XX hours.
Engagements: XXXXX #
- X Week XXXXXX -XX%
- X Month XXXXXX -XX%
- X Months XXXXXXX +39%
- X Year XXXXXXX +397%
Mentions: XX #
- X Week XX -XX%
- X Month XXX -XX%
- X Months XXX +20%
- X Year XXX +79%
Followers: XXXXX #
- X Week XXXXX +0.77%
- X Month XXXXX +2.80%
- X Months XXXXX +40%
- X Year XXXXX +130%
CreatorRank: XXXXXXX #
Social Influence
Social category influence stocks XXXXX% countries XXXXX% finance XXXXX% vc firms #72 travel destinations XXXX% currencies XXXX% cryptocurrencies XXXX% technology brands XXXX%
Social topic influence china 11.11%, the first 5.56%, qiming venture partners #1, $onc #9, shanghai #146, $azn 3.7%, $smmt #11, os 3.7%, at least 1.85%, pts XXXX%
Top accounts mentioned or mentioned by @pistoto2017 @parklover_ja @jacobplieth @oncodailyio
Top assets mentioned One Cash (ONC) AstraZeneca PLC (AZN) Summit Therapeutics Inc. Common Stock (SMMT) Johnson & Johnson (JNJ) Neurocrine Biosciences, Inc. (NBIX) Eli Lilly and Company (LLY) AbbVie Inc (ABBV) Pfizer, Inc. (PFE)
Top Social Posts
Top posts by engagements in the last XX hours
"@JacobPlieth It's from Gracell Biotech. $AZN acquired Gracell in Dec. 2023"
X Link 2025-11-28T15:51Z 3019 followers, XXX engagements
"#3SBio published the Ph2 results of SSGJ-707 #SSGJ707 a bispecific antibody targeting PD-1 and VEGF as a monotherapy in patients with advanced NSCLC . Among the XX pts completed at least one efficacy evaluation ORR and DCR were XXXX% (8/27)/85.2% (23/27) 61.8%(21/34)97.1% (33/34) XXXX% (6/11)/90.9% (10/11) and XX% (1/4)/75% (3/4) at doses of 5mg/kg Q3W 10mg/kg Q3W 20mg/kg Q3W and XX mg/kg Q3W respectively. Select subgroups are summarized in SSGJ-707 10mg/kg Q3W. The ORR were XXXX% (12/22) and 75%(9/12) in non-squamous and squamous pts respectively"
X Link 2025-05-23T08:08Z 3025 followers, 12K engagements
"#Akeso said in its H1 2025 report its lung cancer drug ivonescimab (PD-1/EGFR) for the first time clearly extended overall survival (OS) in a pivotal study. The final analysis of the Phase III HARMONi-A trial met its OS goal showing that ivonescimab delivered "a statistically significant and clinically meaningful OS benefit.""
X Link 2025-08-27T02:31Z 3024 followers, 9776 engagements
"$JNJ reported 2025 Q3 earnings XXX% sales increase to $XX billion BCMA CAR-T therapy Carvyktideveloped in partnership with Legend Biotechsaw significant sales growth. Carvykti achieved total sales of $XXX million in Q3 2025 marking an XXXX% yoy increase. Carvykti's sales have already surpassed $X billion this year totaling $XXXXX billion exceeded its full-year total from 2024 which was $XXX million"
X Link 2025-10-15T09:43Z 3022 followers, 3021 engagements
"Nanjing-based TransThera Sciences announced to enter into a royalty bearing patent assignment and research collaboration agreement with Neurocrine Biosciences $NBIX to develop NLRP3 inhibitors one of the Companys preclinical assets for multiple diseases. ex-Greater China develop manufacture and commercialize rights total potential value of up to US$881.5 million"
X Link 2025-11-04T07:17Z 3024 followers, 1205 engagements
"Ivacta bio an in vivo cell therapy developer announced the completion of an angel round financing exceeding XXX million RMB led by Qiming Venture Partners. Ivacta was was spun off from the in vivo CAR-T platform of GRIT Bio on June XX 2025. Ivacta's in vivo CAR-T therapy developed based on a targeted LNP delivery system focuses on delivering revolutionary treatment options for hematological malignancies and autoimmune diseases"
X Link 2025-11-05T12:28Z 3024 followers, XXX engagements
"3SBio updated Ph2 clinical data for its PD-1/VEGF BsAb SSGJ-707 + chemo in 1L NSCLC at #SITC2025 LBA abstract. SSGJ-707 XX mg/kg the confirmed objective response rate (ORR) was XXXX% in nonsquamous XXXX% in squamous cohort A and XXXX% (paclitaxel; majority pending confirmation) and XXXX% (nab-paclitaxel) in squamous cohort B; with tislelizumab confirmed ORR was XXXX% in nonsquamous and XXXX% in squamous patients. Responses were observed irrespective of PD-L1 expression"
X Link 2025-11-07T15:09Z 3025 followers, XXX engagements
"#SITC2025 LBA Final overall survival analysis of HARMONi-A study comparing ivonescimab plus chemotherapy to chemotherapy alone in patients with EGFR+ NSCLC progressed on EGFR-TKI treatment Akeso $SMMT median OS was XXXX months (95% CI: XXXX 20.0) in the ivonescimab + chemotherapy group vs XXXX months (95% CI: XXXX 16.3) in the placebo + chemotherapy group with a hazard ratio of XXXX (95% CI : XXXX 0.95) and P=0.019 (two-sided) achieving statistical significance at the pre-specified alpha level of XXXX. The 12-month 24-month and 30-month OS rates were XXXX% vs XXXX% XXXX% vs XXXX% and XXXX% vs"
X Link 2025-11-07T16:24Z 3024 followers, 1030 engagements
"$SMMT and Akeso published results from the Ph3 HARMONi-A trial conducted in China and sponsored by Akeso featuring PD-1xVEGF bispecific antibody ivonescimab. The data was presented #SITC2025. The First Phase III Study Testing Ivonescimab Now Represents the First Statistically Significant OS Benefit Achieved by an Ivonescimab Containing Regimen Ivonescimab Plus Chemotherapy Demonstrates Median OS of XXXX Months vs. XXXX Months Respectively for Patients Receiving Ivonescimab Plus Chemotherapy vs. Chemotherapy Alone; OS HR of XXXX (p=0.019)"
X Link 2025-11-09T15:25Z 3024 followers, 4164 engagements
"Akeso's Bispecific Antibody Targeting A and BBB-Expressed Receptor Approved for Alzheimer's Disease Clinical Trials in China It is Akeso's first innovative therapeutic candidate designed to target CNS"
X Link 2025-11-17T07:57Z 3025 followers, 8259 engagements
"Innovent Biologics announced that mazdutide (IBI362) a dual GLP-1/glucagon receptor agonist met the primary endpoint and all key secondary endpoints in the Phase X GLORY-2 study in Chinese adults with moderate-to-severe obesity (BMI XX kg/m or XX kg/m with weight-related comorbidities). At Week XX the mazdutide X mg group achieved a mean weight reduction of XXXXX% compared to XXXX% in the placebo group. XXXX% of participants in the mazdutide X mg group achieved a weight reduction of XX% or more versus XXX% in the placebo group (P0.0001 for all comparisons). The key secondary endpoints"
X Link 2025-11-20T07:44Z 3024 followers, 5442 engagements
"$ONC announced that FDA has accepted and granted Priority Review to a NDA for sonrotoclax a next-generation BCL2 inhibitor for the treatment of adult patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL) following treatment with a Brutons tyrosine kinase (BTK) inhibitor"
X Link 2025-11-27T15:36Z 3024 followers, 1519 engagements
"Using ADCs to deliver RAS inhibitors has emerged as a hotspot in drug development due to its ability to broaden the therapeutic window and minimize off-target toxicity. According to patent information (WO2025/051241 A1) GenFleet Therapeutics is developing an EGFR/HER3 bispecific antibody-ADC carrying a pan-RAS inhibitor payload. Now at the recent AACR-NCI-EORTC 2025 conference Adlai Nortye $ANL unveiled its Pan-RAS(ON)-conjugated ADC candidate AN4035. /1 🧵👇🏻"
X Link 2025-11-30T15:52Z 3024 followers, 6940 engagements
"5/ Bystander Effect Cytotoxic against XX cancer cell lines regardless of KRAS mutation status Stronger bystander killing compared to topoisomerase inhibitor payloads"
X Link 2025-11-30T15:52Z 3024 followers, XXX engagements
"6/ Efficacy HPAC and CL40 CDX models: X mg/kg single dose XX% tumor regression XX mg/kg 8589% regression Across XX NSCLC CRC and pancreatic cancer PDX models: Overall antitumor response rate of 73%"
X Link 2025-11-30T15:52Z 3024 followers, XXX engagements
"Keymed Biosciences previously disclosed two ADCs: - CMG901 (AZD-0901 sonesitatug vedotin) a CLDN18.2-targeted ADC co-developed with Lepu Biopharma which entered a global collaboration with $AZN in 2023. - CM518D1 a CDH17-targeted ADC for which an IND was filed in China in January 2025. Recently published PCT patent WO2025/242098 reveals Keymeds third ADC candidate a CEACAM5-targeted ADC. - The humanized lead mAb1 H6K3 exhibits stronger binding affinity to both human and cynomolgus monkey CEACAM5 than the reference antibody (ref1). - No cross-reactivity with mouse CEACAM5 or other CEACAM"
X Link 2025-11-30T16:13Z 3021 followers, 2803 engagements
"Hengrui announced that it nominated and appointed Guoxin Zhu former Vice President of Molecule Discovery Lilly Research Laboratories $LLY as its senior vice president"
X Link 2025-12-04T15:42Z 3025 followers, 1009 engagements
"NHSA unveiled an updated version of its national medical insurance drug list and the inaugural edition of the commercial insurance innovative drug list. New lists will be formally implemented nationwide starting January X 2026. The updated national medical insurance drug list has added XXX drugs among which XX are innovative pharmaceuticals. The commercial insurance innovative drug list included XX drugs for the treatment of tumors rare diseases and Alzheimer's among others. The XX drugs are: X. Velaglucerase beta CANbridge X. Sapropterin Shandong New Time Pharma X. Teduglutide $TAK 4."
X Link 2025-12-07T15:16Z 3022 followers, 1578 engagements
"SynRx Therapeutics announced the completion of a Series A #financing round exceeding RMB XXX million led by the Zhejiang 4+1 Biomedical and High-End Medical Device Industry Fund. SynRx Therapeutics has concentrated on unmet clinical needs in the DNA damage repair space. Its core product SYN818 is a highly selective DNA polymerase (Pol) inhibitor. It has entered Phase 1b clinical trials where it is being evaluated in combination with olaparib in patients with locally advanced or metastatic solid tumors with BRCA mutations and/or homologous recombination repair pathway defects. The companys"
X Link 2025-12-08T15:58Z 3023 followers, XXX engagements
"yes Ascletis said when ASC30 was titrated weekly its vomiting rate was about half that of $LLY's oral GLP-1 orforglipron. The findings suggest "a potential best-in-class profile of ASC30 for both weight loss and GI tolerability" said Jinzi Jason Wu founder CEO and chairman of Ascletis"
X Link 2025-12-09T09:17Z 3024 followers, XX engagements
"$ONC and $ABBV s Pharmacyclics have decided to voluntarily dismiss the patent lawsuit the Big Pharma firm brought against its competitor over their BTK inhibitors. BeOne announced the decision in a securities filing to HKSE. The move comes after the U.S. Patent and Trademark Office (USPTO) recently invalidated all claims of AbbVies patent No. 11672803 which underpinned the Illinois pharmas patent infringement lawsuit filed in 2023"
X Link 2025-10-03T15:36Z 3024 followers, 1001 engagements
"$ZLAB Zai Lab has registered its first Ph3 clinical trial of ZL-1310 (zocilurtatug pelitecan) This randomized open-label clinical trial (n=665) aims to evaluate the efficacy and safety of ZL-1310 (at two dose levels) compared with investigator's choice (Tarlatamab Topotecan Lurbinectedin or Amrubicin) in patients with relapsed SCLC. The primary endpoints are cORR and OS. ZL-1310 is an ADC targeting DLL3 discovered by MediLink Therapeutics using its TAMLIN technology platform. In April 2023 Zai Lab and MediLink Therapeutics entered an agreement acquiring global rights for ZL-1310. In ASCO2025"
X Link 2025-10-21T12:45Z 3024 followers, 3688 engagements
"Shanghai Longwood Biopharmaceuticals announced the completion of a Series B+ #financing worth hundreds of millions of RMB led by Qiming Venture Partners. Longwood was founded in 2012 by Dr. Wang Zhe. Dr. Zhe Wang a professor at Nankai University and an expert in medicinal chemistry. He completed his postdoctoral research at Harvard University under the tutelage of Nobel Laureate in Chemistry Elias J. Corey. Longwood focuses on the development of innovative drugs in the fields of immunotherapy antiviral therapy autoimmune diseases and tumor immunotherapy. Its core products: LW231 bi-functional"
X Link 2025-10-29T15:59Z 3024 followers, XXX engagements
"ESMO Asia 2025: Hansoh Pharmaceutical will deliver an oral presentation featuring the first clinical data for its B7H3-targeted ADC HS-20093 (GSK5764227) in a NSCLC subgroup This ESMO Asia presentation reports results from the NSCLC cohort of ARTEMIS-001 treated with XXX or XXXX mg/kg HS-20093 every X weeks (Q3W). As of the data cutoff (January XX 2025) among XXX NSCLC patients treated at XXX mg/kg (n=93) or XXXX mg/kg (n=74): - XXXX% had adenocarcinoma XXXX% had squamous cell carcinoma - Median age: XXXX years - XXXX% current or former smokers - XXXX% with baseline brain metastases - Median"
X Link 2025-12-03T14:15Z 3024 followers, 2099 engagements
"Kelun-Biotech and Crescent Biopharma Announce Strategic Partnership to Develop and Commercialize Novel Oncology Therapeutics Crescent has granted Kelun-Biotech exclusive rights to research develop manufacture and commercialize CR-001 (PD-1 x VEGF bispecific antibody) in Greater China. Kelun-Biotech has granted Crescent exclusive rights to research develop manufacture and commercialize SKB105 (ITGB6 ADC) in the United States Europe and all other markets outside of Greater China. The partnership includes the development of these candidates as monotherapies and also the evaluation of CR-001 in"
X Link 2025-12-04T15:51Z 3023 followers, XXX engagements
"Cathay Capital has announced that it is leading Hundreds of millions of RMB Series A financing round for EMBIOS through its Sanofi-Cathay Healthcare Innovation Fund. EMBIOS has pioneered a key pipeline centered on the CXCR3 pathway. Its lead candidate YSC001 is designed around this pathway: on one hand it blocks the binding of CXCR3 to its ligands reducing the abnormal migration of immune cells to lesion sites; on the other it selectively eliminates these cells. EMBIOS submitted IND application for YSC001 last month. Sanofi Cathay Healthcare Innovation Fund:"
X Link 2025-12-08T04:35Z 3024 followers, 1647 engagements
"BeOne Medicines (formerly BeiGene) $ONC registered an international Ph1 clinical trial for BG-75098 monotherapy or in combination for the treatment of advanced solid tumors. This Ph1 trial plans to enroll XXX patients with advanced solid tumors. The combination therapy regimens include combination with the CDK4 inhibitor BGB-43395 and fulvestrant. According to information disclosed by BeOne at its 2025 R&D Day BG-75098 is a CDK2 CDAC and also a potential first-in-class CDK2 degrader featuring superior potency selectivity and pharmacokinetic (PK) characteristics"
X Link 2025-11-11T15:44Z 3023 followers, 1390 engagements
"SanegeneBio a clinical-stage biotech developing RNAi therapeutics announced the closing of Series B #financing round raising over $XXX million. The Series B financing was led by a well-known industrial investor. SanegeneBio has R&D operations in Boston Shanghai and Suzhou. The company has initiated clinical trials for four experimental medicines to-date and has LEAD tissue-selective RNAi delivery technology"
X Link 2025-12-08T16:07Z 3024 followers, 8198 engagements
"$PFE announced it has entered into an exclusive global collaboration and license agreement with YaoPharma a subsidiary of Shanghai Fosun Pharmaceutical for the development manufacturing and commercialization of YP05002 a small molecule GLP-1 receptor agonist currently in Phase X development for chronic weight management. upfront: $XXX million milestones: up to $XXXXX billion Pfizer plans to conduct combination studies of YP05002 with its glucose-dependent insulinotropic polypeptide receptor (GIPR) antagonist PF-07976016 currently in Phase X development and with other small molecules in its"
X Link 2025-12-10T05:02Z 3024 followers, 2590 engagements
"I also have a CRO (clinical study service) company and monitor some trials for GLP-1R drugs. Serious or frequently vomit and diarrhea commonly lead the patients cannot receive higher dosage it is a problem to those severe obesity patients. Of course in China BMI30 patients is relatively rare"
X Link 2025-12-10T05:08Z 3024 followers, XX engagements
"D3 Bio a global clinical-stage biotech focused on the discovery and development of innovative oncology therapeutics announced the completion of a $XXX million Series B #financing round. The funding round was backed by IDG Capital and SongQing Capital. Existing investors WuXi AppTec's Corporate Venture Fund Temasek HSG MPCi and Medicxi also contributed to the round. Lead asset elisrasib (D3S-001) is KRAS G12C inhibitor"
X Link 2025-12-10T11:55Z 3024 followers, 1349 engagements
"Elpiscience presented phase X clinical trial results for its internally developed bispecific antibody ES014 in an oral presentation at the ESMO Asia 2025. ES014 is a first-in-class CD39/TGF- bispecific antibody Among the X DT patients treated with ES014 X achieved partial response (PR) and X achieved stable disease (SD) resulting in an objective response rate (ORR) of XX% and a disease control rate (DCR) of 100%"
X Link 2025-12-10T13:03Z 3024 followers, XXX engagements